Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

기사 요약

The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.